Reduce the burden of daily medication with Buvidal
Long-acting medication for the treatment of opioid dependence
Long-acting medication for the treatment of opioid dependence
Most people in the UK receiving Opioid Dependence Treatment (ODT) are prescribed daily medication that often requires supervised self-administration.
Whilst this standard of care is effective for many patients, the routine of daily supervised treatment inevitably impacts on their lives.
Buvidal is a prolonged release medication for the treatment of opioid dependence and is available as either a weekly or monthly subcutaneous injection.
Buvidal contains the active ingredient buprenorphine, which suppresses withdrawal and cravings associated with opioid dependence.
Due to its slow-release properties, patients treated with Buvidal no longer face the potentially restrictive and stigmatising routine of daily visits to a pharmacy or drug treatment service for supervised medication.
Information at your fingertips
Our website is designed to not only give you lots of useful information and resources about Buvidal, but also advice on how to introduce Buvidal into a drug treatment service.
It is intended for a broad audience of healthcare professionals and other relevant decision makers working in the field of drug addiction – including commissioners, prescribers, pharmacists, nursing and professional support staff.
In addition to sharing our own knowledge and expertise we have also invited HCPs and patients to share their experience of Buvidal in the hope that this real world and lived experience can help others understand both the benefits and practicalities of delivering Buvidal treatment.
Patient Story
Before you learn more about Buvidal, watch our introductory video which tells the story of Cullan – a Buvidal patient.
